Blog 6/27/22 Discovery of IRAKIMiDs: Dual-Mechanism Degraders Targeting IRAK4 and IMiDSubstrates for Oncology 6/8/22 Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications 6/6/22 Discovery and targeted mass spectrometry-based proteomics: Enabling technologies advancing IRAK4 protein degrader along the drug discovery pipeline into the clinic 6/5/22 Phase 1 Study of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors 6/5/22 Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 6/1/22 STAT3 degraders inhibit Th17 development and cytokine production resulting in profound inhibition of collagen-induced autoimmune murine arthritis 5/20/22 Kinetics of IRAK4 Degradation and Impact on Functional Response in Circulating Immune Cells and Skin Cell Subsets 5/10/22 Non-Clinical Safety Considerations when Developing Targeted Protein Degraders 5/3/22 Selective IRAK4 Degradation, Not Kinase Inhibition, Blocks TLR-activated NF-kB and p38 Signaling Leading to broad Cytokine Inhibition 5/3/22 STAT3 Degraders Inhibit Cellular Activation, Cytokine Production, and Th17 Development, Resulting in Profound Inhibition of Autoimmunity in the MOG-EAE Model of CNS Inflammation
